{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:13:27Z","timestamp":1789787607453,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized for its excellent local tumor control. The efficacy and safety of concurrent atezo-bev with RT for highly advanced HCC has been minimally explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this preliminary retrospective study, we assessed patients with highly advanced HCC, characterized by Vp4 portal vein thrombosis or tumors exceeding 50% of liver volume, who received concurrent atezo-bev and RT (group A). Group A included 13 patients who received proton radiation at a dose of 72.6 GyE in 22 fractions, and one patient who received photon radiation at a dose of 54 Gy in 18 fractions. This group was compared with 34 similar patients treated atezo-bev alone as a control (group B). The primary objectives were to evaluate the objective response rate (ORR), overall survival (OS), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline characteristics were similar between groups, except for a higher incidence of Vp4 portal vein thrombosis in group A (78.6% vs. 21.4%, P\u2005=\u2005.05). Group A achieved a higher ORR (50.0% vs. 11.8%, P\u2005&amp;lt;\u2005.01) and a longer OS (not reached vs. 5.5 months, P\u2005=\u2005.01) after a median follow-up of 5.2 months. Multivariate analysis indicated that concurrent RT independently favored longer OS (hazard ratio: 0.18; 95% CI, 0.05-0.63, P\u2005&amp;lt;\u2005.01). Group A did not increase any grade adverse events (78.6% vs. 58.8%, P\u2005=\u2005.19) or severe adverse events of grade\u2005\u2265\u20053 (14.3% vs. 14.7%, P\u2005=\u2005.97) compared to group B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The concurrent high-dose external beam radiotherapy appears to safely enhance the effectiveness of atezolizumab plus bevacizumab for highly advanced patients with HCC. Further studies are warranted to confirm these findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae048","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T18:42:42Z","timestamp":1711478562000},"page":"e922-e931","source":"Crossref","is-referenced-by-count":34,"title":["Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3618","authenticated-orcid":false,"given":"Chung-Wei","family":"Su","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Yi-Liang","family":"Shen","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Radiation Oncology and Proton Therapy Center, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"Clinical Metabolomics Core Lab, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Shen","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Radiation Oncology and Proton Therapy Center, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Mo","family":"Hou","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of General Surgery, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Din-Li","family":"Tsan","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Radiation Oncology and Proton Therapy Center, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital (Built and Operated by Chang Gung Memorial Hospital) , New Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Nursing, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Mei","family":"Chai","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Nursing, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3190","authenticated-orcid":false,"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-2679","authenticated-orcid":false,"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Gastroenterology and Hepatology, New Taipei Municipal Tucheng Hospital (Built and Operated by Chang Gung Memorial Hospital) , New Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2024070511393638700_CIT0001","first-page":"1598","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume-title":"J Hepatol","author":"Rumgay","year":"2022"},{"key":"2024070511393638700_CIT0002","first-page":"681","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume-title":"J Hepatol","author":"Reig","year":"2022"},{"key":"2024070511393638700_CIT0003","first-page":"502","article-title":"Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies","volume-title":"Liver Int","author":"Tandon","year":"2009"},{"key":"2024070511393638700_CIT0004","first-page":"CT009","article-title":"Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)","volume-title":"Cancer Res","author":"Finn","year":"2021"},{"key":"2024070511393638700_CIT0005","first-page":"116","article-title":"Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma","volume-title":"Radiat Oncol","author":"Gkika","year":"2017"},{"key":"2024070511393638700_CIT0006","first-page":"101","article-title":"Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review","volume-title":"World J Hepatol","author":"Kalogeridi","year":"2015"},{"key":"2024070511393638700_CIT0007","first-page":"28","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO Clinical Practice Guideline","volume-title":"Pract Radiat Oncol","author":"Apisarnthanarax","year":"2022"},{"key":"2024070511393638700_CIT0008","first-page":"202","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume-title":"Int J Radiat Oncol Biol Phys","author":"Juloori","year":"2023"},{"key":"2024070511393638700_CIT0009","first-page":"1901","article-title":"Outcomes and toxicities of modern combined modality therapy with atezolizumab plus bevacizumab and radiation therapy for hepatocellular carcinoma","volume-title":"Cancers (Basel)","author":"Manzar","year":"2022"},{"key":"2024070511393638700_CIT0010","first-page":"1107542","article-title":"Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study","volume-title":"Front Immunol","author":"Wang","year":"2023"},{"issue":"4","key":"2024070511393638700_CIT0011","first-page":"1606","article-title":"Proton beam radiotherapy combined with anti-PD1\/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"12","author":"Su","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2024070511393638700_CIT0012","first-page":"723","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume-title":"Hepatology","author":"Marrero","year":"2018"},{"key":"2024070511393638700_CIT0013","first-page":"S94","article-title":"Radiation-associated liver injury","volume-title":"Int J Radiat Oncol Biol Phys","author":"Pan","year":"2010"},{"key":"2024070511393638700_CIT0014","first-page":"2774","article-title":"Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis","volume-title":"World J Hepatol","author":"Stine","year":"2015"},{"key":"2024070511393638700_CIT0015","first-page":"e000032","article-title":"Predictors of hepatic decompensation after TACE for hepatocellular carcinoma","volume-title":"BMJ Open Gastroenterol","author":"Kohla","year":"2015"},{"key":"2024070511393638700_CIT0016","first-page":"1163","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume-title":"Lancet","author":"Kudo","year":"2018"},{"key":"2024070511393638700_CIT0017","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume-title":"NEJM Evidence","author":"Abou-Alfa","year":"2022"},{"key":"2024070511393638700_CIT0018","first-page":"4073","article-title":"IMbrave150: exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and\/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study","volume-title":"J Clin Oncol","author":"Breder","year":"2021"},{"key":"2024070511393638700_CIT0019","first-page":"806","article-title":"Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume-title":"Strahlenther Onkol","author":"Lee","year":"2014"},{"key":"2024070511393638700_CIT0020","first-page":"1631","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume-title":"J Clin Oncol","author":"Bujold","year":"2013"},{"key":"2024070511393638700_CIT0021","first-page":"96","article-title":"Consensus development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)","volume-title":"Liver Cancer","author":"Hsu","year":"2015"},{"key":"2024070511393638700_CIT0022","first-page":"eabl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume-title":"Sci Immunol","author":"Hsieh","year":"2022"},{"key":"2024070511393638700_CIT0023","first-page":"760090","article-title":"Clinical values and markers of radiation-induced liver disease for hepatocellular carcinoma with portal vein tumor thrombus treated with stereotactic body radiotherapy","volume-title":"Front Oncol","author":"Jia","year":"2021"},{"key":"2024070511393638700_CIT0024","first-page":"3053","article-title":"The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial","volume-title":"Cancer","author":"Bush","year":"2011"},{"key":"2024070511393638700_CIT0025","first-page":"1479","article-title":"Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma","volume-title":"Int J Radiat Oncol Biol Phys","author":"Kawashima","year":"2011"},{"key":"2024070511393638700_CIT0026","first-page":"999","article-title":"Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation","volume-title":"J Gastrointest Oncol","author":"Hasan","year":"2019"},{"key":"2024070511393638700_CIT0027","first-page":"73","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume-title":"Int J Radiat Oncol Biol Phys","author":"Barney","year":"2013"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/7\/e922\/58449062\/oyae048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/7\/e922\/58449062\/oyae048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T11:39:46Z","timestamp":1720179586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/7\/e922\/7634978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae048","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,3,26]]}}}